Suppr超能文献

天然化合物作为醛糖还原酶(AR)抑制剂的来源用于治疗糖尿病并发症:小型综述。

Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.

机构信息

Chitkara School of Basic Sciences, Chitkara University, Himachal Pradesh, India.

Chitkara College of Pharmacy, Chitkara University, Punjab, India.

出版信息

Curr Drug Metab. 2020;21(14):1091-1116. doi: 10.2174/1389200221666201016124125.

Abstract

BACKGROUND

Aldol reductase (AR) is the polyol pathway's main enzyme that portrays a crucial part in developing 'complications of diabetes' involving cataract, retinopathy, nephropathy, and neuropathy. These diabetic abnormalities are triggered tremendously via aggregation of sorbitol formation (catalyzed by AR) in the polyol pathway. Consequently, it represents an admirable therapeutic target and vast research was done for the discovery of novel molecules as potential AR inhibitors for diabetic complications.

OBJECTIVE

This review article has been planned to discuss an outline of diabetic complications, AR and its role in diabetic complications, natural compounds reported as AR inhibitors, and benefits of natural/plant derived AR inhibitors for the management of diabetic abnormalities.

RESULTS

The goal of AR inhibition remedy is to stabilize the increased flux of blood glucose and sorbitol via the 'polyol pathway' in the affected tissues. A variety of synthetic inhibitors of AR have been established such as tolrestat and sorbinil, but both of these face limitations including low permeability and health problems. Pharmaceutical industries and other scientists were also undertaking work to develop newer, active, and 'safe' AR inhibitors from natural sources. Therefore, several naturally found molecules were documented to possess a potent inhibitory action on AR activity.

CONCLUSION

Natural inhibitors of AR appeared as harmless pharmacological agents for controlling diabetic complications. The detailed literature throughout this article shows the significance of herbal extracts and phytochemicals as prospective useful AR inhibitors in treating diabetic complications.

摘要

背景

醛糖还原酶(AR)是多元醇途径的主要酶,在涉及白内障、视网膜病变、肾病和神经病的“糖尿病并发症”的发展中起着至关重要的作用。这些糖尿病异常是通过多元醇途径中山梨醇形成(由 AR 催化)的聚集而极大地引发的。因此,它代表了一个令人钦佩的治疗靶点,并且已经进行了大量的研究来发现新的分子作为治疗糖尿病并发症的潜在 AR 抑制剂。

目的

本文旨在讨论糖尿病并发症概述、AR 及其在糖尿病并发症中的作用、作为 AR 抑制剂的天然化合物以及天然/植物衍生的 AR 抑制剂在糖尿病异常管理中的益处。

结果

AR 抑制疗法的目标是通过受影响组织中的“多元醇途径”稳定增加的血糖和山梨醇通量。已经建立了多种 AR 的合成抑制剂,例如 tolrestat 和 sorbinil,但两者都存在局限性,包括低通透性和健康问题。制药行业和其他科学家也在努力从天然来源开发更新的、有效的和“安全”的 AR 抑制剂。因此,有几种天然存在的分子被证明对 AR 活性具有很强的抑制作用。

结论

AR 的天然抑制剂似乎是控制糖尿病并发症的无害药理制剂。本文通篇的详细文献表明,草药提取物和植物化学物质作为治疗糖尿病并发症的潜在有用 AR 抑制剂具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验